An Experimental Study of the Pharmacokinetics of the Antitumor Drug Aurumacryl


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Тек жазылушылар үшін

Аннотация

The distribution of the antitumor drug aurumacryl (intraperitoneally injected at a dose of 100 mg/kg) in the bodies of animals with Lewis lung carcinoma was studied. The determination of aurumacryl in the tumors and organs (blood, liver, kidneys, lungs, spleen, and brain) of mice was carried out for 48 h by measuring the gold content in the test tissues using inductively coupled plasma mass spectrometry. We found the preferential accumulation of the drug in the kidneys with an extremely low gold content in the brain and a relatively uniform distribution of aurumacryl between the tumor, liver, lung, and spleen tissues.

Авторлар туралы

L. Ostrovskaya

Emanuel Institute of Biochemical Physics

Хат алмасуға жауапты Автор.
Email: larros@list.ru
Ресей, ul. Kosygina 4, Moscow, 119334

D. Korman

Emanuel Institute of Biochemical Physics

Email: larros@list.ru
Ресей, ul. Kosygina 4, Moscow, 119334

J. Burmiy

Institute of Microelectronic Technology and Ultra-High-Purity Materials

Email: larros@list.ru
Ресей, ul. Akademika Osipyana 6, Chernogolovka, 142432

V. Kuzmin

Emanuel Institute of Biochemical Physics

Email: larros@list.ru
Ресей, ul. Kosygina 4, Moscow, 119334

N. Bluhterova

Emanuel Institute of Biochemical Physics

Email: larros@list.ru
Ресей, ul. Kosygina 4, Moscow, 119334

M. Fomina

Emanuel Institute of Biochemical Physics

Email: larros@list.ru
Ресей, ul. Kosygina 4, Moscow, 119334

V. Rikova

Emanuel Institute of Biochemical Physics

Email: larros@list.ru
Ресей, ul. Kosygina 4, Moscow, 119334

R. Guliev

Emanuel Institute of Biochemical Physics

Email: larros@list.ru
Ресей, ul. Kosygina 4, Moscow, 119334

K. Abzaeva

Favorsky Irkutsk Institute of Chemistry, Siberian Branch

Email: larros@list.ru
Ресей, ul. Favorskogo 1, Irkutsk, 664033

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML

© Pleiades Publishing, Inc., 2018